DGAP-News: Epigenomics AG / Key word(s): Change of Personnel
29.11.2017 / 21:41
Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive Vice President Finance and a Member of the Management Board (Vorstand)
Berlin (Germany) and Germantown, MD (U.S.A.), November 29, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced today that the Supervisory Board appointed Albert Weber Executive Vice President of Finance effective January 1, 2018. Mr. Weber, who has worked at Epigenomics for the past seventeen years, will become a member of the Executive Board of Epigenomics and continue to oversee the company’s financial, accounting and controlling departments.
Mr. Weber (54), has more than 25 years of corporate finance experience including the last seventeen years at Epigenomics. Prior to this recent appointment Mr. Weber was the Senior Vice President of Finance, Accounting and Controlling for Epigenomics. Prior to joining the company, Albert served as Manager Controlling of Pironet AG, a Cologne based IT start-up and previously at EMI Group Germany as the Manager Treasury and Corporate Accounting. Mr. Weber has experience in capital raises, all corporate finance functions and IPO’s. He has a degree in Business Administration from Cologne University and is certified in IFRS accounting.
Heino von Prondzynski, Chairman of the Supervisory Board, stated: “The Supervisory Board is very happy to recognize Albert’s hard work and dedication to Epigenomics by adding him the Executive Board. Mr. Weber’s financial experience will be a valued benefit to the Executive Board as the company prepares for the next stage of growth.”
“I am excited to join the Executive Board,” said Mr. Weber. “I’ve been with Epigenomics for seventeen years and I’m truly excited about the amazing opportunity in front of the company. I look forward to helping the organization transform the colorectal screening market.”
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics’ second product, Epi proLung(R), is in development as a blood-based test for lung cancer detection.
For more information, visit www.epigenomics.com.
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Phone:||+49 30 24345-0|
|Fax:||+49 30 24345-555|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|